Tag: biomedical
-
Univ. Research Execs See Science Economic Benefits
15 July 2015. Senior research executives at 10 U.S. universities described the benefits of scientific research to their campuses, communities, and nation at a roundtable discussion today in Washington, D.C. The forum, organized by the Science Coalition and Association of American Universities, also described perils of uneven federal research funding as well as related dangers…
-
Bristol-Myers Squibb, S.C. Med School Partner on Fibrosis
15 July 2015. Medical University of South Carolina and pharmaceutical company Bristol-Myers Squibb are collaborating on drug discovery research to better understand the science behind fibrosis diseases, leading to new treatments. Financial and intellectual property aspects of the partnership were not disclosed. Fibrosis is the growth of excess tissue that occurs in response to injury…
-
Trial Testing Respiratory Muscle Drug for ALS Patients
14 July 2015. Biopharmaceutical company Cytokinetics is beginning a late-stage clinical trial of a drug designed to slow the decline of respiratory muscle functions in people with amyotrophic lateral sclerosis, or ALS, a neurodegenerative disorder. In addition, Cytokinetics, in South San Francisco, California, received a $1.5 million grant from the ALS Association supporting the trial,…
-
FDA Clears Biotech Cancer Therapies for Early Trials
13 July 2015. Biotechnology company Blueprint Medicines says U.S. Food and Drug Administration accepted new drug applications on its two lead products, clearing the way for trials with humans. The Cambridge, Massachusetts enterprise is developing cancer therapies, with its lead products targeting liver and gastrointestinal tumors. Blueprint develops cancer therapies that limit the actions of…
-
Spinal Stimulation Start-Up Wins $200K State Award
13 July 2015. PathMaker Neurosystems Inc., a developer of non-invasive devices that stimulate the spinal cord to relieve muscle weakness and paralysis, received a $200,000 award from a Massachusetts science funding agency. The grant was made by Massachusetts Life Sciences Center as part of its life sciences milestone achievement program. PathMaker’s technology uses electronic current…
-
Univ. of Arizona Spin-Off Licenses Cancer Therapy
10 July 2015. A new company spun-off from University of Arizona licensed a cancer therapy based on research by a pharmacy faculty member at the school, also the company’s founder. Synactix Pharmaceuticals Inc. in Tucson is founded by pharmacology professor Hong-yu Li and postdoctoral fellow Brendan Fett. Li’s lab at Arizona studies cancer therapeutics, particularly…
-
Oxford, Ludwig Institute Launch Immunotherapy Start-Up
9 July 2015. University of Oxford in the U.K. and Ludwig Cancer Research Institute are forming a spin-off enterprise to commercialize research by an Oxford immunology professor for cancer therapies. Financial details of the partnership to create iOx Therapeutics were not disclosed. The new company is commercializing research from the lab of Oxford immunologist Vincenzo…
-
Antibodies Isolated for Chikungunya Virus
9 July 2015. Researchers at Vanderbilt University in Nashville isolated 13 antibodies from a person infected with the chikungunya virus shown to possibly prevent and treat infections in lab mice. The team led by James Crowe, director of Vanderbilt’s Vaccine Center, published its findings yesterday in the journal Cell Host & Microbe. Chikungunya is a disease…
-
Allergan Acquires Merck Migraine Therapies
8 July 2015. The pharmaceutical company Allergan is licensing therapies for treatment and prevention of migraines being developed by Merck, another pharma company. The agreement is expected to bring Merck $250 million over the next year, as well as undisclosed milestone and royalty payments from Allergan. Migraine is a neurological syndrome causing severe headaches along with…
-
FDA Grants Orphan Status to Brain Cancer Surgery Aid
7 July 2015. The U.S. Food and Drug Administration is granting orphan drug status to an engineered peptide that illuminates brain cancer cells making them easier to surgically remove. The treatment, code-named BLZ-100, is made by Blaze Bioscience, a biotechnology company in Seattle. Blaze Bioscience is a spin-off enterprise from Fred Hutchinson Cancer Research Center,…